Asset Details
Do you wish to reserve the book?
Plumbagin suppresses chronic periodontitis in rats via down-regulation of TNF-α, IL-1β and IL-6 expression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Plumbagin suppresses chronic periodontitis in rats via down-regulation of TNF-α, IL-1β and IL-6 expression
Do you wish to request the book?
Plumbagin suppresses chronic periodontitis in rats via down-regulation of TNF-α, IL-1β and IL-6 expression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Plumbagin suppresses chronic periodontitis in rats via down-regulation of TNF-α, IL-1β and IL-6 expression
2017
Overview
Chronic periodontitis （CP） is one of the most common oral diseases, which causes alveolar bone absorption and tooth loss in adults. in this study we aimed to investigate the potential of plumbagin （PL）, a widely-investigated active compound extracted from the traditional Chinese herb Plumbago zeylanica L in treating CP. Human periodontal ligament stem cells （PDLSCs） were used for in vitro studies, whereas an animal model of CP was established in SD rats by ligation＋Porphyromonas gingivalis （Pg） stimulation. The rats were injected with PL （2, 4, and 6 mg·kg^-1·d^-1, ip） for 4 weeks. Treatment of PDLSCs with TNF-α （10 ng/mL） markedly stimulated the expression of the proinflammatory cytokines TNF-α, IL-1β and IL-6, as well as the chemokines CCL-2 and CCL-5, which were dose- dependently suppressed by co-treatment with PL （1.25-5 μmol/L）. Furthermore, PL （3.75 pmol/L） markedly suppressed TNF-α-induced activation of the MAPK, NF-κB and JAK/STAT signaling pathways in PDLSCs. In consistence with the in vitro studies, PL administration significantly decreased the expression of TNF-α, IL-1β and IL-6 in gingiva of the rat with CP, with the dosage 4 mg·kg^-1·d^-1 showing the best anti-inflammatory effect. Moreover, PL administration decelerated bone destruction in the rat with CP, evidenced by the aveolar bone loss （ABL） and H＆E staining results. In conclusion, PL suppresses CP progression in rats by downregulating the expressions of TNF-α, IL-1β and IL-6 and inhibiting the MAPK, NF-κB and JAK/STAT signaling pathways.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Anti-Inflammatory Agents - therapeutic use
/ Biomedical and Life Sciences
/ Chronic Periodontitis - drug therapy
/ Dose-Response Relationship, Drug
/ Down-Regulation - drug effects
/ Female
/ IL-1β
/ IL-6
/ Interleukin-1beta - metabolism
/ Naphthoquinones - therapeutic use
/ Original
/ Rats
/ SD大鼠
/ TNF-α
/ Tumor Necrosis Factor-alpha - metabolism
/ Vaccine
/ 人牙周膜干细胞
/ 慢性
/ 牙周炎
/ 白花
